HDL-cholesterol elevation associated with fingolimod and dimethyl fumarate therapies in multiple sclerosis

Abstract

Fingolimod and DMF therapies are associated with a specific increase in HDL in PwMS. Further studies are required to validate these findings and their potential implication as biomarker of reduced inflammatory state and/or reduced risk of neurodegeneration or cardiovascular comorbidity.